© Reuters. Theranos CEO Elizabeth Holmes speaks on stage at the Beauty Women of the Year Awards where she gets an award, in the Manhattan borough of New york city
By Suzanne Barlyn PHILADELPHIA (Reuters) – The chief executive of embattled blood screening company Theranos Inc on Monday said the independently held company is working diligently to remedy all its outstanding problems involving its product and lab operations. Speaking prior to some 1,000 researchers at the American Association for Scientific Chemistry conference in Philadelphia, Theranos CEO Elizabeth Holmes described new products that she said are “unique from the operations of our clinical laboratories” that must come under examination. Prior to introducing Holmes, association president Patricia Jones stated the organization does not support Theranos. “We’re all aware that there must been some recommendations about whether we’ll see some science today and the viability of Theranos innovation,” Jones stated. The business, when valued at $9 billion, wased established by Holmes in 2003 to craft an ingenious blood testing device that would give quicker results utilizing simply one drop of blood. It ran into problem after the Wall Street Journal published a series of articles beginning last October suggesting the gadgets were flawed and incorrect. Holmes last month was disallowed by U.S. regulators from owning or operating a laboratory for at least two years and, in a squashing blow, the Centers for Medicare & & Medicaid Solutions withdrawed an essential certificate for its California lab and terminated the center’s approval to receive government payments. Walgreens Boots Alliance terminated its relationship with the business in June and closed operations at all 40 Theranos Wellness Centers at its drug stores in Arizona..
Disclaimer: Blend Media want to remind you that the data consisted of in this site is not always real-time nor precise. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, therefore costs may not be accurate and may differ from the actual market price, suggesting prices are a sign and not proper for trading purposes. For that reason Blend Media does n`t bear any obligation for any trading losses you may incur as an outcome of using this information. Combination Media or anybody included with Fusion Media will decline any liability for loss or damage as an outcome of reliance on the information consisting of data, quotes, charts and buy/sell signals contained within this website. Please be completely informed concerning the dangers and costs related to trading the monetary markets, it is one of the riskiest investment types possible.